Andrew Hill

Summary

Publications

  1. ncbi request reprint Predicting HIV care costs using CD4 counts from clinical trials
    Andrew Hill
    Department of Pharmacology, University of Liverpool, UK, and Tibotec BVBA, Mechelen, Belgium
    Am J Manag Care 13:524-8. 2007
  2. doi request reprint Identification of new genotypic cut-off levels to predict the efficacy of lopinavir/ritonavir and darunavir/ritonavir in the TITAN trial
    A Hill
    Pharmacology Research Laboratories, University of Liverpool, Liverpool, UK
    HIV Med 10:620-6. 2009
  3. doi request reprint Effects of first-line use of nucleoside analogues, efavirenz, and ritonavir-boosted protease inhibitors on lipid levels
    Andrew Hill
    Pharmacology Research Laboratories, University of Liverpool, Liverpool, UK
    HIV Clin Trials 10:1-12. 2009
  4. ncbi request reprint Risk factors for gastrointestinal adverse events in HIV treated and untreated patients
    Andrew Hill
    Pharmacology Research Laboratories, University of Liverpool, Liverpool, UK
    AIDS Rev 11:30-8. 2009
  5. doi request reprint Designing and interpreting HIV noninferiority trials in naive and experienced patients
    Andrew Hill
    Pharmacology Research Laboratories, University of Liverpool, 70 Pembroke Place, Liverpool L69 3GF, UK
    AIDS 22:913-21. 2008
  6. ncbi request reprint Analysis of costs by CD4 count category for the darunavir/r 600/100 mg bid and control protease inhibitor arms of the POWER 1 and 2 trials
    Andrew Hill
    Department of Pharmacology, University of Liverpool, Tibotec BVBA, United Kingdom
    HIV Clin Trials 8:303-10. 2007
  7. ncbi request reprint The costs of full suppression of plasma HIV RNA in highly antiretroviral-experienced patients
    Andrew M Hill
    Pharmacology Research Laboratories, University of Liverpool, Liverpool, UK
    AIDS Rev 13:41-8. 2011
  8. ncbi request reprint Analysis of treatment costs for HIV RNA reductions and CD4 increases for darunavir versus other antiretrovirals in treatment-experienced, HIV-infected patients
    Andrew M Hill
    University of Liverpool, United Kingdom
    HIV Clin Trials 8:121-31. 2007
  9. doi request reprint Optimizing HIV treatment
    Andrew Hill
    Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK
    Curr Opin HIV AIDS 8:34-40. 2013
  10. doi request reprint Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients
    A Hill
    Pharmacology Research Laboratories, University of Liverpool, Liverpool, UK
    HIV Med 10:527-35. 2009

Collaborators

Detail Information

Publications24

  1. ncbi request reprint Predicting HIV care costs using CD4 counts from clinical trials
    Andrew Hill
    Department of Pharmacology, University of Liverpool, UK, and Tibotec BVBA, Mechelen, Belgium
    Am J Manag Care 13:524-8. 2007
    ..To predict the effects of a new antiretroviral agent on the costs of care in a US HIV care setting...
  2. doi request reprint Identification of new genotypic cut-off levels to predict the efficacy of lopinavir/ritonavir and darunavir/ritonavir in the TITAN trial
    A Hill
    Pharmacology Research Laboratories, University of Liverpool, Liverpool, UK
    HIV Med 10:620-6. 2009
    ..The TITAN trial evaluated LPV/r vs. darunavir/ritonavir (DRV/r) in treatment-experienced patients with viral load >1000 copies/mL. This analysis aimed to re-evaluate resistance algorithms for LPV/r in the TITAN trial...
  3. doi request reprint Effects of first-line use of nucleoside analogues, efavirenz, and ritonavir-boosted protease inhibitors on lipid levels
    Andrew Hill
    Pharmacology Research Laboratories, University of Liverpool, Liverpool, UK
    HIV Clin Trials 10:1-12. 2009
    ..Treatment with ritonavir-boosted protease inhibitors or efavirenz and nucleoside analogues leads to rises in lipids, which might contribute to cardiovascular risk...
  4. ncbi request reprint Risk factors for gastrointestinal adverse events in HIV treated and untreated patients
    Andrew Hill
    Pharmacology Research Laboratories, University of Liverpool, Liverpool, UK
    AIDS Rev 11:30-8. 2009
    ..The percentage of patients who use medications to lessen the symptoms of diarrhea and other gastrointestinal adverse events should also be reported...
  5. doi request reprint Designing and interpreting HIV noninferiority trials in naive and experienced patients
    Andrew Hill
    Pharmacology Research Laboratories, University of Liverpool, 70 Pembroke Place, Liverpool L69 3GF, UK
    AIDS 22:913-21. 2008
  6. ncbi request reprint Analysis of costs by CD4 count category for the darunavir/r 600/100 mg bid and control protease inhibitor arms of the POWER 1 and 2 trials
    Andrew Hill
    Department of Pharmacology, University of Liverpool, Tibotec BVBA, United Kingdom
    HIV Clin Trials 8:303-10. 2007
    ..HIV-infected people with low CD4 counts are at higher risk of AIDS and incur increased health care costs from in-patient stays and medications...
  7. ncbi request reprint The costs of full suppression of plasma HIV RNA in highly antiretroviral-experienced patients
    Andrew M Hill
    Pharmacology Research Laboratories, University of Liverpool, Liverpool, UK
    AIDS Rev 13:41-8. 2011
    ..In summary, when treating highly treatment-experienced patients, cost-savings could be made by using combinations of newer antiretrovirals in preference to recycled nucleoside analogs and enfuvirtide...
  8. ncbi request reprint Analysis of treatment costs for HIV RNA reductions and CD4 increases for darunavir versus other antiretrovirals in treatment-experienced, HIV-infected patients
    Andrew M Hill
    University of Liverpool, United Kingdom
    HIV Clin Trials 8:121-31. 2007
    ..The additional cost per incremental 25 cell rise in CD4 count, or 0.5 log reduction in HIV RNA, was calculated for 8 antiretrovirals using pivotal clinical trials data...
  9. doi request reprint Optimizing HIV treatment
    Andrew Hill
    Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK
    Curr Opin HIV AIDS 8:34-40. 2013
    ..An additional 19 million people will need to start treatment in the future, as their HIV disease progresses. Funding for Universal Access to HIV treatment has been restricted by the Global Financial Crisis...
  10. doi request reprint Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients
    A Hill
    Pharmacology Research Laboratories, University of Liverpool, Liverpool, UK
    HIV Med 10:527-35. 2009
    ..The ACTG 5202 and BICOMBO trials suggested higher efficacy for TDF/FTC, whereas the HEAT trial showed no efficacy difference between the nucleoside reverse transcriptase inhibitor (NRTI) backbones...
  11. ncbi request reprint Discordant conclusions from HIV clinical trials--an evaluation of efficacy endpoints
    Andrew Hill
    Department of Pharmacology, University of Liverpool, Liverpool, UK
    Antivir Ther 10:367-74. 2005
    ....
  12. ncbi request reprint Analysis of genotypic and phenotypic clinical cut-off levels for ritonavir-boosted saquinavir
    A Hill
    Department of Pharmacology, University of Liverpool, Liverpool, UK
    HIV Med 7:67-74. 2006
    ..Using Virtual Phenotype, a 12.3-fold upper cut-off level was determined from analysis of large cohort databases. These genotypic and phenotypic algorithms need to be validated in larger prospective studies...
  13. ncbi request reprint Balancing effectiveness and access to HIV treatment in the developing world
    Andrew Hill
    Pharmacology Research Laboratories, University of Liverpool, 70 Pembroke Place, Liverpool, UK
    AIDS 21:361-3. 2007
  14. ncbi request reprint Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment
    Andrew Hill
    Liverpool University, Liverpool, UK
    Expert Opin Pharmacother 8:679-88. 2007
    ....
  15. ncbi request reprint Prediction of clinical benefits of ritonavir-boosted TMC114 from treatment effects on CD4 counts and HIV RNA
    A Hill
    Department of Pharmacology, University of Liverpool, Liverpool, UK
    HIV Med 8:234-40. 2007
    ..The aim of the study was to predict reductions in progression to AIDS/death associated with the treatment benefit of antiretrovirals on CD4 counts and HIV RNA in the era of highly active antiretroviral therapy (HAART)...
  16. ncbi request reprint Relative antiviral efficacy of ritonavir-boosted darunavir and ritonavir-boosted tipranavir vs. control protease inhibitor in the POWER and RESIST trials
    A Hill
    Department of Pharmacology, University of Liverpool, Liverpool, UK
    HIV Med 8:259-64. 2007
    ....
  17. ncbi request reprint Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients
    Jennifer Ford
    Department of Pharmacology and Therapeutics, University of Liverpool, 70 Pembroke Place, Liverpool L69 3GF, and PK Research Ltd, St Stephen s Centre, Chelsea and Westminster Hospital, London, UK
    J Antimicrob Chemother 58:1009-16. 2006
    ..To examine cellular and plasma concentrations of atazanavir when given in combination with saquinavir/ritonavir in HIV+ patients...
  18. ncbi request reprint Modelling-based prediction of clinical benefits from etravirine in the TMC125-C223 trial
    Andrew Hill
    Pharmacology Laboratories, Liverpool University, UK
    HIV Clin Trials 8:68-76. 2007
    ..To predict the decrease in progression to AIDS or death based on the treatment benefit of etravirine over active control on CD4 counts and HIV RNA...
  19. ncbi request reprint Should we now adopt the HIV-RNA < 50 copy endpoint for clinical trials of antiretroviral-experienced as well as naive patients?
    Andrew Hill
    Department of Pharmacology, University of Liverpool, UK
    AIDS 21:1651-3. 2007
    ..HIV-RNA suppression below 50 copies/ml should now become the standard efficacy endpoint across trials of both naive and experienced patients...
  20. doi request reprint Resistance at virological failure using boosted protease inhibitors versus nonnucleoside reverse transcriptase inhibitors as first-line antiretroviral therapy--implications for sustained efficacy of ART in resource-limited settings
    Andrew Hill
    Pharmacology Research Laboratories, Liverpool University, United Kingdom
    J Infect Dis 207:S78-84. 2013
    ..We aimed to examine whether first-line use of 2 NRTIs plus a boosted protease inhibitor (bPI) could protect against emergence of NRTI resistance mutations, compared to the use of 2 NRTIs plus 1 NNRTI...
  21. pmc Pharmacokinetic interaction between TMC114/ritonavir and tenofovir disoproxil fumarate in healthy volunteers
    Richard M W Hoetelmans
    Tibotec BVBA, Mechelen, Belgium
    Br J Clin Pharmacol 64:655-61. 2007
    ..An open-label crossover study was conducted in HIV - healthy volunteers to investigate the potential for a pharmacokinetic interaction between TMC114/r and tenofovir...
  22. pmc Intracellular and plasma pharmacokinetics of saquinavir-ritonavir, administered at 1,600/100 milligrams once daily in human immunodeficiency virus-infected patients
    Jennifer Ford
    Department of Pharmacology and Therapeutics, University of Liverpool, 70 Pembroke Pl, Block H, First Floor, Liverpool L69 3GF, United Kingdom
    Antimicrob Agents Chemother 48:2388-93. 2004
    ..The intracellular t(1/2)s of saquinavir and ritonavir were longer than the plasma t(1/2)s, indicating that intracellular drug may be available at a time when concentrations in plasma are below the minimum effective concentration...
  23. doi request reprint Etravirine limits the emergence of darunavir and other protease inhibitor resistance-associated mutations in the DUET trials
    Monika Peeters
    Tibotec BVBA, Mechelen, Belgium
    AIDS 24:921-4. 2010
    ....
  24. pmc Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study
    Laura J Else
    Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom
    Antimicrob Agents Chemother 56:1427-33. 2012
    ..68 to 0.99), and 0.70 (0.61 to 0.82), respectively. We found that 3TC at 150 mg is not bioequivalent to the standard regimen of 300 mg, indicating that saturation of cytosine phosphorylation pathways is not achieved at a dose of 150 mg...